EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas

Devraj Basu, Arnaud Bewley, Steven M. Sperry, Kathleen T. Montone, Phyllis A. Gimotty, Kati Rasanen, Nicole D. Facompre, Gregory S. Weinstein, Hiroshi Nakagawa, J. Alan Diehl, Anil K. Rustgi, Meenhard Herlyn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Squamous cell carcinomas (SCC) with an infiltrative invasion pattern carry a higher risk of treatment failure. Such infiltrative invasion may be mediated by a mesenchymal-like subpopulation of malignant cells that we have previously shown to arise from epithelial-mesenchymal transition (EMT) and resist epidermal growth factor receptor (EGFR) targeting. Here, we show that SCCs with infiltrative, high-risk invasion patterns contain abundant mesenchymal-like cells, which are rare in tumors with low-risk patterns. This cellular heterogeneity was modeled accurately in three-dimensional culture using collagen-embedded SCC spheroids, which revealed distinct invasive fronts created by collective migration of E-cadherin-positive cells versus infiltrative migration of individual mesenchymal-like cells. Because EGFR expression by mesenchymal-like cells was diminished in the spheroid model and in human SCCs, we hypothesized that SCCs shift toward infiltrative invasion mediated by this subpopulation during anti-EGFR therapy. Anti-EGFR treatment of spheroids using erlotinib or cetuximab enhanced infiltrative invasion by targeting collective migration by E-cadherin-positive cells while sparing mesenchymal-like cells; by contrast, spheroid invasion in absence of mesenchymal-like cells was abrogated by erlotinib. Similarly, cetuximab treatment of xenografts containing mesenchymal-like cells created an infiltrative invasive front composed of this subpopulation, whereas no such shift was observed upon treating xenografts lacking these cells. These results implicate mesenchymal-like SCC cells as key mediators of the infiltrative invasion seen in tumors with locally aggressive behavior. They further show that EGFR inhibition can promote an infiltrative invasion front composed of mesenchymal-like cells preferentially in tumors where they are abundant before therapy. Mol Cancer Ther; 12(10); 2176-86.

Original languageEnglish (US)
Pages (from-to)2176-2186
Number of pages11
JournalMolecular Cancer Therapeutics
Volume12
Issue number10
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Squamous Cell Carcinoma
Neoplasms
Cadherins
Heterografts
Epithelial-Mesenchymal Transition
Treatment Failure
Collagen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas. / Basu, Devraj; Bewley, Arnaud; Sperry, Steven M.; Montone, Kathleen T.; Gimotty, Phyllis A.; Rasanen, Kati; Facompre, Nicole D.; Weinstein, Gregory S.; Nakagawa, Hiroshi; Diehl, J. Alan; Rustgi, Anil K.; Herlyn, Meenhard.

In: Molecular Cancer Therapeutics, Vol. 12, No. 10, 10.2013, p. 2176-2186.

Research output: Contribution to journalArticle

Basu, D, Bewley, A, Sperry, SM, Montone, KT, Gimotty, PA, Rasanen, K, Facompre, ND, Weinstein, GS, Nakagawa, H, Diehl, JA, Rustgi, AK & Herlyn, M 2013, 'EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas', Molecular Cancer Therapeutics, vol. 12, no. 10, pp. 2176-2186. https://doi.org/10.1158/1535-7163.MCT-12-1210
Basu, Devraj ; Bewley, Arnaud ; Sperry, Steven M. ; Montone, Kathleen T. ; Gimotty, Phyllis A. ; Rasanen, Kati ; Facompre, Nicole D. ; Weinstein, Gregory S. ; Nakagawa, Hiroshi ; Diehl, J. Alan ; Rustgi, Anil K. ; Herlyn, Meenhard. / EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas. In: Molecular Cancer Therapeutics. 2013 ; Vol. 12, No. 10. pp. 2176-2186.
@article{46eec528332245549f4da7d2ed90b76b,
title = "EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas",
abstract = "Squamous cell carcinomas (SCC) with an infiltrative invasion pattern carry a higher risk of treatment failure. Such infiltrative invasion may be mediated by a mesenchymal-like subpopulation of malignant cells that we have previously shown to arise from epithelial-mesenchymal transition (EMT) and resist epidermal growth factor receptor (EGFR) targeting. Here, we show that SCCs with infiltrative, high-risk invasion patterns contain abundant mesenchymal-like cells, which are rare in tumors with low-risk patterns. This cellular heterogeneity was modeled accurately in three-dimensional culture using collagen-embedded SCC spheroids, which revealed distinct invasive fronts created by collective migration of E-cadherin-positive cells versus infiltrative migration of individual mesenchymal-like cells. Because EGFR expression by mesenchymal-like cells was diminished in the spheroid model and in human SCCs, we hypothesized that SCCs shift toward infiltrative invasion mediated by this subpopulation during anti-EGFR therapy. Anti-EGFR treatment of spheroids using erlotinib or cetuximab enhanced infiltrative invasion by targeting collective migration by E-cadherin-positive cells while sparing mesenchymal-like cells; by contrast, spheroid invasion in absence of mesenchymal-like cells was abrogated by erlotinib. Similarly, cetuximab treatment of xenografts containing mesenchymal-like cells created an infiltrative invasive front composed of this subpopulation, whereas no such shift was observed upon treating xenografts lacking these cells. These results implicate mesenchymal-like SCC cells as key mediators of the infiltrative invasion seen in tumors with locally aggressive behavior. They further show that EGFR inhibition can promote an infiltrative invasion front composed of mesenchymal-like cells preferentially in tumors where they are abundant before therapy. Mol Cancer Ther; 12(10); 2176-86.",
author = "Devraj Basu and Arnaud Bewley and Sperry, {Steven M.} and Montone, {Kathleen T.} and Gimotty, {Phyllis A.} and Kati Rasanen and Facompre, {Nicole D.} and Weinstein, {Gregory S.} and Hiroshi Nakagawa and Diehl, {J. Alan} and Rustgi, {Anil K.} and Meenhard Herlyn",
year = "2013",
month = "10",
doi = "10.1158/1535-7163.MCT-12-1210",
language = "English (US)",
volume = "12",
pages = "2176--2186",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas

AU - Basu, Devraj

AU - Bewley, Arnaud

AU - Sperry, Steven M.

AU - Montone, Kathleen T.

AU - Gimotty, Phyllis A.

AU - Rasanen, Kati

AU - Facompre, Nicole D.

AU - Weinstein, Gregory S.

AU - Nakagawa, Hiroshi

AU - Diehl, J. Alan

AU - Rustgi, Anil K.

AU - Herlyn, Meenhard

PY - 2013/10

Y1 - 2013/10

N2 - Squamous cell carcinomas (SCC) with an infiltrative invasion pattern carry a higher risk of treatment failure. Such infiltrative invasion may be mediated by a mesenchymal-like subpopulation of malignant cells that we have previously shown to arise from epithelial-mesenchymal transition (EMT) and resist epidermal growth factor receptor (EGFR) targeting. Here, we show that SCCs with infiltrative, high-risk invasion patterns contain abundant mesenchymal-like cells, which are rare in tumors with low-risk patterns. This cellular heterogeneity was modeled accurately in three-dimensional culture using collagen-embedded SCC spheroids, which revealed distinct invasive fronts created by collective migration of E-cadherin-positive cells versus infiltrative migration of individual mesenchymal-like cells. Because EGFR expression by mesenchymal-like cells was diminished in the spheroid model and in human SCCs, we hypothesized that SCCs shift toward infiltrative invasion mediated by this subpopulation during anti-EGFR therapy. Anti-EGFR treatment of spheroids using erlotinib or cetuximab enhanced infiltrative invasion by targeting collective migration by E-cadherin-positive cells while sparing mesenchymal-like cells; by contrast, spheroid invasion in absence of mesenchymal-like cells was abrogated by erlotinib. Similarly, cetuximab treatment of xenografts containing mesenchymal-like cells created an infiltrative invasive front composed of this subpopulation, whereas no such shift was observed upon treating xenografts lacking these cells. These results implicate mesenchymal-like SCC cells as key mediators of the infiltrative invasion seen in tumors with locally aggressive behavior. They further show that EGFR inhibition can promote an infiltrative invasion front composed of mesenchymal-like cells preferentially in tumors where they are abundant before therapy. Mol Cancer Ther; 12(10); 2176-86.

AB - Squamous cell carcinomas (SCC) with an infiltrative invasion pattern carry a higher risk of treatment failure. Such infiltrative invasion may be mediated by a mesenchymal-like subpopulation of malignant cells that we have previously shown to arise from epithelial-mesenchymal transition (EMT) and resist epidermal growth factor receptor (EGFR) targeting. Here, we show that SCCs with infiltrative, high-risk invasion patterns contain abundant mesenchymal-like cells, which are rare in tumors with low-risk patterns. This cellular heterogeneity was modeled accurately in three-dimensional culture using collagen-embedded SCC spheroids, which revealed distinct invasive fronts created by collective migration of E-cadherin-positive cells versus infiltrative migration of individual mesenchymal-like cells. Because EGFR expression by mesenchymal-like cells was diminished in the spheroid model and in human SCCs, we hypothesized that SCCs shift toward infiltrative invasion mediated by this subpopulation during anti-EGFR therapy. Anti-EGFR treatment of spheroids using erlotinib or cetuximab enhanced infiltrative invasion by targeting collective migration by E-cadherin-positive cells while sparing mesenchymal-like cells; by contrast, spheroid invasion in absence of mesenchymal-like cells was abrogated by erlotinib. Similarly, cetuximab treatment of xenografts containing mesenchymal-like cells created an infiltrative invasive front composed of this subpopulation, whereas no such shift was observed upon treating xenografts lacking these cells. These results implicate mesenchymal-like SCC cells as key mediators of the infiltrative invasion seen in tumors with locally aggressive behavior. They further show that EGFR inhibition can promote an infiltrative invasion front composed of mesenchymal-like cells preferentially in tumors where they are abundant before therapy. Mol Cancer Ther; 12(10); 2176-86.

UR - http://www.scopus.com/inward/record.url?scp=84885646767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885646767&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-12-1210

DO - 10.1158/1535-7163.MCT-12-1210

M3 - Article

C2 - 23939378

AN - SCOPUS:84885646767

VL - 12

SP - 2176

EP - 2186

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -